Clinical trial
Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children
NCT00364793 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00364793 |
|---|---|
| Title | Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children |
| Official title | An Open-label Study of Liquid and Sprinkled Formulations of Efavirenz Administered in Combination With Didanosine and Emtricitabine in HIV-infected Infants and Children 3 Months to 6 Years of Age. |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC) |
| Enrollment | 56 |
| Start date | Feb 1, 2007 |
| Primary completion | Dec 1, 2011 |
| Completion | Jul 1, 2013 |
| First posted | Aug 16, 2006 |
| Last update posted | Apr 29, 2014 |
| Countries | Argentina, Colombia, Mexico, Panama, South Africa, Thailand |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: